高危骨髓增生异常综合征:移植的时机选择

[1]	McClune BL,Weisdorf DJ,Pedersen TL,et al.Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome[J].J Clin Oncol,2010,28:1878-1887.
[2]	Laribi K,Bolle D,Alani M,et al.Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine[J].Exp Hematol,2018,65:34-37.
[3]	Tachibana T,Tanaka M,Numata A,et al.Pretransplant serum ferritin has a prognostic influence on allogeneic transplant regardless of disease risk[J].Leuk Lymphoma,2012,53:456-461.
[4]	Waszczuk-Gajda A,Madry K,Machowicz R,et al.Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes:Results from the First Polish MDS-PALG Registry[J].Adv Clin Exp Med,2016,25:633-641.
[5]	Cremers EMP,de Witte T,de Wreede L,et al.A prospective non-interventional study on the impact of transfusion burden and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation[J].Leuk Lymphoma,2019 Apr 18:1-11.doi:10.1080/10428194.2019.1594215.[Epub ahead of print].
[6]	Della Porta MG,Alessandrino EP,Bacigalupo A,et al.Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R[J].Blood,2014,123:2333-2342.
[7]	Kim YJ,Jung SH,Hur EH,et al.TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome[J].Leuk Res,2018,74:97-104.
[8]	Lindsley RC,Saber W,Mar BG,et al.Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation[J].N Engl J Med,2017,376:536-547.
[9]	Saber W,Cutler CS,Nakamura R,et al.Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)[J].Blood,2013,122:1974-1982.
[10]	Robin M,Porcher R,Ades L,et al.Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS[J].Bone Marrow Transplant,2013,48:1296-1301.
[11]	Robin M,Ruggeri A,Labopin M,et al.Comparison of unrelated cord bloodand peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen:a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy &Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party[J].Biol Blood Marrow Transplant,2015,21:489-495.
[12]	Ke P,Bao XB,Hu XH,et al.Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients[J].Bone Marrow Transplant,2018,53:162-168.
[13]	Zheng CC,Zhu XY,Tang BL,et al.Double vs.single cord blood transplantation in adolescent and adult hematological malignancies with heavier body weight (≥ 50 kg)[J].Hematology,2018,23:96-104.
[14]	Zhu Xiaoyu.Favorable outcomes of single-unit cord blood transplantation as salvaged treatment for advanced hematologic malignancies[J].Blood,2017,130(Suppl 1):5538.
[15]	Platzbecker U.Who benefits from allogeneic transplantation for myelodysplastic syndromes?:new insights[J].Hematology Am Soc Hematol Educ Program,2013,2013:522-528.
[16]	Sohn SK,Moon JH.Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS[J].Crit Rev Oncol Hematol,2015,95:243-250.
[17]	Malcovati L,Hellstrom-Lindberg E,Bowen D,et al.Diagnosis and treatment of primary myelodysplastic syndromes in adults:recommendations from the European LeukemiaNet[J].Blood,2013,122:2943-2964.
[18]	Shaffer BC,Ahn KW,Hu ZH,et al.Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome[J].J Clin Oncol,2016,34:1864-1871.
[19]	Wermke M,Gloaguen S,Platzbecker U.Preparing patients with myelodysplastic syndrome for transplant when is pre-transplant cytoreductive therapy appropriate?[J].Curr Hematol Malig Rep,2015,10:329-333.
[20]	Yang T,Lin Q,Ren J,et al.A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies[J].Oncotarget,2016,7:78773-78786.
[21]	Brierley CK,Steensma DP.Allogeneic stem cell transplantation in myelodysplastic syndromes:does pretransplant clonal burden matter?[J].Curr Opin Hematol,2016,23:167-174.
[22]	Buchholz S,Dammann E,Stadler M,et al.Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk,relapsed,or refractory acute myeloid leukemia and advanced myelodysplastic syndrome[J].Eur J Haematol,2012,88:52-60.
[23]	Montalban-Bravo G,Kanagal-Shamanna R,Sasaki K,et al.NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy[J].Blood Adv,2019,3:922-933.
[24]	Scott BL,Pasquini MC,Logan B,et al.Results of a phase III randomized,multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML):Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901[abstract].Blood,2015,126:Abstract LBA-8.
[25]	Kroger N,Brand R,Niederwieser D,et al.Reduced intensity vs.standard conditioning followed by allogeneic stem cell transplantation for patients with MDS or secondary AML:a prospective,randomized phase III study of the Chronic Malignancies Working Party of the EBMT (RICMACTrial)[abstract].Blood,2014,124:Abstract 320.
[26]	Alatrash G,Kidwell KM,Thall PF,et al.Reduced intensity vs.myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS[J].Bone Marrow Transplant,2018 Dec 10.doi:10.1038/s41409-018-0405-0.[Epub ahead of print].
[27]	Gerds AT,Gooley TA,Estey EH,et al.Pretransplantation therapy with azacitidine vs induction chemotherapyand posttransplantation outcome in patients with MDS[J].Biol Blood Marrow Transplant,2012,18:1211-1218.
[28]	Damaj G,Duhamel A,Robin M,et al.Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes:a study by the Societe Franaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies[J].J Clin Oncol,2012,30:4533-4540.
[29]	Flotho C,Sommer S,Lübbert M.DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia[J].Semin Cancer Biol,2018,51:68-79.
[30]	Modi D,Kim S,Singh V,et al.Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome[J].Leuk Lymphoma,2019 Apr 23:1-9.doi:10.1080/10428194.2019.1605070.[Epub ahead of print].
[31]	Brierley CK,Steensma DP.Allogeneic stem cell transplantation in myelodysplastic syndromes:does pretransplant clonal burden matter[J].Curr Opin Hematol,2016,23:167-174.
[32]	Yahng SA,Kim M,Kim TM,et al.Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts[J].Oncotarget,2017,8:12342-12354.
[33]	Kako S,Kanda Y,Kato J,et al.The bridge treatment selected at the decision for transplantation did not affect the outcomes in patients with MDS[J].Hematol Oncol,2017,35:341-349.